Market Closed -
Nasdaq
04:00:00 2024-06-12 pm EDT
|
5-day change
|
1st Jan Change
|
2.79
USD
|
-1.06%
|
|
-11.43%
|
-8.22%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,157
|
7,400
|
4,350
|
372.5
|
158.9
|
146.1
|
-
|
-
|
Enterprise Value (EV)
1 |
2,821
|
6,431
|
3,618
|
-106.4
|
-126.6
|
47.43
|
154.4
|
107.3
|
P/E ratio
|
-57.6
x
|
-50.5
x
|
-16.4
x
|
-1.12
x
|
-0.61
x
|
-0.78
x
|
-0.71
x
|
-1.32
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-58
x
|
-47.4
x
|
-13.6
x
|
0.32
x
|
0.49
x
|
-0.24
x
|
-0.7
x
|
-0.4
x
|
EV / FCF
|
-71.3
x
|
-71.1
x
|
-14.7
x
|
0.44
x
|
0.65
x
|
-0.86
x
|
-
|
-
|
FCF Yield
|
-1.4%
|
-1.41%
|
-6.79%
|
229%
|
155%
|
-116%
|
-
|
-
|
Price to Book
|
9.25
x
|
8.72
x
|
6.62
x
|
0.86
x
|
0.6
x
|
1.03
x
|
9.01
x
|
4.16
x
|
Nbr of stocks (in thousands)
|
43,884
|
50,370
|
51,305
|
52,025
|
52,286
|
52,383
|
-
|
-
|
Reference price
2 |
71.95
|
146.9
|
84.78
|
7.160
|
3.040
|
2.790
|
2.790
|
2.790
|
Announcement Date
|
3/16/20
|
3/1/21
|
3/1/22
|
3/28/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-48.65
|
-135.5
|
-266
|
-337.6
|
-259
|
-196
|
-221.4
|
-266.7
|
EBIT
1 |
-49.19
|
-136
|
-267.1
|
-341.4
|
-277.3
|
-196.8
|
-230.5
|
-270.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-47.36
|
-133.1
|
-267
|
-333.8
|
-260.5
|
-183.8
|
-239.8
|
-361.4
|
Net income
1 |
-47.36
|
-133.1
|
-267
|
-333.8
|
-260.5
|
-183.8
|
-239.8
|
-361.4
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.250
|
-2.910
|
-5.160
|
-6.390
|
-4.970
|
-3.567
|
-3.932
|
-2.106
|
Free Cash Flow
1 |
-39.58
|
-90.43
|
-245.6
|
-243.5
|
-195.5
|
-55
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
3/1/21
|
3/1/22
|
3/28/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-93.05
|
-95.77
|
-92.07
|
-79.48
|
-74.07
|
-74.62
|
-84.83
|
-54.5
|
-63.37
|
-46.06
|
-48.96
|
-49.84
|
-51.09
|
-48.67
|
-48.42
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-93.16
|
-95.71
|
-90.63
|
-77.04
|
-70.45
|
-70.78
|
-80.19
|
-50.01
|
-59.52
|
-43.04
|
-43.25
|
-44
|
-44.8
|
-
|
-
|
Net income
1 |
-93.16
|
-95.71
|
-90.63
|
-77.04
|
-70.45
|
-70.78
|
-80.19
|
-50.01
|
-59.52
|
-43.04
|
-43.25
|
-44
|
-44.8
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.790
|
-1.830
|
-1.740
|
-1.470
|
-1.350
|
-1.350
|
-1.530
|
-0.9500
|
-1.130
|
-0.8200
|
-0.8783
|
-0.9159
|
-0.9440
|
-0.8885
|
-0.8908
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/1/22
|
5/10/22
|
8/9/22
|
11/9/22
|
3/28/23
|
5/15/23
|
8/14/23
|
11/14/23
|
3/28/24
|
5/15/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
8.24
|
-
|
Net Cash position
1 |
336
|
969
|
732
|
479
|
286
|
98.7
|
-
|
38.9
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.0372
x
|
-
|
Free Cash Flow
1 |
-39.6
|
-90.4
|
-246
|
-243
|
-196
|
-55
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-21.9%
|
-22.1%
|
-35%
|
-60.7%
|
-74.2%
|
-65.5%
|
-236%
|
-493%
|
ROA (Net income/ Total Assets)
|
-21%
|
-18.7%
|
-27.1%
|
-42.5%
|
-45.5%
|
-36.3%
|
-
|
-
|
Assets
1 |
225.5
|
713.1
|
985.8
|
785.4
|
573
|
506.2
|
-
|
-
|
Book Value Per Share
2 |
7.780
|
16.80
|
12.80
|
8.330
|
5.060
|
2.710
|
0.3100
|
0.6700
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.44
|
7
|
17
|
37
|
41.4
|
-
|
2.58
|
2.56
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
3/1/21
|
3/1/22
|
3/28/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
2.79
USD Average target price
3.5
USD Spread / Average Target +25.45% Consensus |
1st Jan change
|
Capi.
|
---|
| -8.22% | 148M | | +16.93% | 124B | | +17.01% | 109B | | -7.23% | 23.84B | | +1.98% | 22.42B | | -14.29% | 17.5B | | -6.79% | 16.61B | | -37.63% | 16.43B | | +2.17% | 13.4B | | +24.42% | 11.47B |
Bio Therapeutic Drugs
|